Dongfeng Pharmaceutical's Degludec/Aspart Dual Insulin Approved for Market

36Kr reports that Dongfeng Pharmaceutical announced its self-developed degludec/aspart dual insulin injection has officially received approval from the National Medical Products Administration (NMPA) for market launch, covering both cartridge and prefilled pen specifications for the treatment of type 2 diabetes. Public records show that Novo Nordisk is the originator of degludec/aspart dual insulin; this formulation combines long-acting steady glycemic control with rapid prandial glucose reduction and has not yet been included in the national centralized procurement. According to data from Kangmei Consulting, sales of this product in domestic retail and tiered hospital channels are projected to total approximately 2.5 billion yuan in 2025.